Overexpression of phosphorylated p27Kip1 at threonine 187 may predict outcome in aggressive B-cell lymphomas

Leukemia and Lymphoma

Volumn 52, Issue 5, 2011, Pages 814-822

  Sirinian, Chaido ^a   Symeonidis, Argiris ^a   Giannakoulas, Nikolaos ^b   Zolota, Vassiliki ^a   Melachrinou, Maria ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b UNIVERSITY OF THESSALY   (Greece)

Author keywords

B cell lymphoma; outcome; p27Kip1; pThr187 p27Kip1

Indexed keywords

ALBUMIN; BETA 2 MICROGLOBULIN; HEMOGLOBIN; KI 67 ANTIGEN; LACTATE DEHYDROGENASE; PROTEIN P27; THREONINE;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; B CELL LYMPHOMA; CANCER PATIENT; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; LYMPHOCYTOMA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P27; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, B-CELL; PHOSPHORYLATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL ANALYSIS; THREONINE;

EID: 79955071970     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.555026     Document Type: Article

References (44)

1. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999;13: 1501-1512. (Pubitemid 29297917)
2. Slingerland J, Pagano M. Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol 2000;183: 10-17. (Pubitemid 30130220)
3. Catzavelos C, Bhattacharya N, Ung YC, et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 1997;3:227-230. (Pubitemid 27064710)
4. Palmqvist R, Stenling R, Oberg A, Landberg G. Prognostic significance of p27(Kip1) expression in colorectal cancer: a clinico-pathological characterization. J Pathol 1999;188:18-23. (Pubitemid 29197309)
5. Cheville JC, Lloyd RV, Sebo TJ, et al. Expression of p27kip1 in prostatic adenocarcinoma. Mod Pathol 1998;11:324-328.
6. Erlanson M, Portin C, Linderholm B, Lindh J, Roos G, Landberg G. Expression of cyclin E and the cyclin-dependent kinase inhibitor p27 in malignant lymphomas-prognostic implications. Blood 1998;92:770-777. (Pubitemid 28355458)
7. Erlanson M, Landberg G. Prognostic implications of p27 and cyclin E protein contents in malignant lymphomas. Leuk Lymphoma 2001;40:461-470. (Pubitemid 32303237)
8. Moller MB. P27 in cell cycle control and cancer. Leuk Lymphoma 2000;39:19-27. (Pubitemid 30657804)
9. Tsvetkov LM, Yeh KH, Lee SJ, Sun H, Zhang H. p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27. Curr Biol 1999;9:661-664.
10. Nakayama KI, Hatakeyama S, Nakayama K. Regulation of the cell cycle at the G1-S transition by proteolysis of cyclin E and p27Kip1. Biochem Biophys Res Commun 2001;282:853-860. (Pubitemid 32924572)
11. Hershko D, Bornstein G, Ben-Izhak O, et al. Inverse relation between levels of p27(Kip1) and of its ubiquitin ligase subunit Skp2 in colorectal carcinomas. Cancer 2001;91:1745-1751. (Pubitemid 32377961)
12. Masuda TA, Inoue H, Sonoda H, et al. Clinical and biological significance of S-phase kinase-associated protein 2 (Skp2) gene expression in gastric carcinoma: modulation of malignant phenotype by Skp2 overexpression, possibly via p27 proteolysis. Cancer Res 2002;62:3819-3825. (Pubitemid 34728867)
13. Signoretti S, Di Marcotullio L, Richardson A, et al. Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest 2002;110:633-641. (Pubitemid 34988787)
14. Osoegawa A, Yoshino I, Tanaka S, et al. Regulation of p27 by S-phase kinase-associated protein 2 is associated with aggressiveness in non-small-cell lung cancer. J Clin Oncol 2004;22:4165-4173. (Pubitemid 41185187)
15. Oliveira AM, Okuno SH, Nascimento AG, Lloyd RV. Skp2 protein expression in soft tissue sarcomas. J Clin Oncol 2003;21:722-727. (Pubitemid 46621909)
16. Chiarle R, Fan Y, Piva R, et al. S-phase kinase-associated protein 2 expression in non-Hodgkin's lymphoma inversely correlates with p27 expression and defines cells in S phase. Am J Pathol 2002;160:1457-1466. (Pubitemid 34411648)
17. Lim MS, Adamson A, Lin Z, et al. Expression of Skp2, a p27(Kip1) ubiquitin ligase, in malignant lymphoma: correlation with p27(Kip1) and proliferation index. Blood 2002;100:2950-2956.
18. Seki R, Okamura T, Koga H, et al. Prognostic significance of the F-box protein Skp2 expression in diffuse large B-cell lymphoma. Am J Hematol 2003;73:230-235. (Pubitemid 36898878)
19. Latres E, Chiarle R, Schulman BA, et al. Role of the F-box protein Skp2 in lymphomagenesis. Proc Natl Acad Sci USA 2001;98:2515-2520. (Pubitemid 32209513)
20. Troncone G, Martinez JC, Iaccarino A, et al. p27Kip1 is expressed in proliferating cells in its form phosphorylated on threonine 187. BMC Clin Pathol 2005;5:3.
21. Kase S, Yoshida K, Nakayama KI, et al. Phosphorylation of p27(KIP1) in the developing retina and retinoblastoma. Int J Mol Med 2005;16:257-262.
22. Kase S, Yoshida K, Ohgami K, Shiratori K, Ohno S, Nakayama KI. Phosphorylation of p27(KIP1) in the mitotic cells of the corneal epithelium. Curr Eye Res 2006;31:307-312.
23. Harris NL, Jaffe ES, Stein H, Vardiman JW, editors. World Health Organization classification of tumours. Pathology and genetics: tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.
24. Hermans J, Krol AD, van Groningen K, et al. International prognostic index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades. Blood 1995;86:1460-1463.
25. Ma XM, Liu Y, Guo JW, Liu JH, Zuo LF. Relation of overexpression of S phase kinase-associated protein 2 with reduced expression of p27 and PTEN in human gastric carcinoma. World J Gastroenterol 2005;11:6716-6721. (Pubitemid 43072718)
26. Yang G, Ayala G, De Marzo A, et al. Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin Cancer Res 2002;8: 3419-3426. (Pubitemid 35340716)
27. Woenckhaus C, Maile S, Uffmann S, et al. Expression of Skp2 and p27KIP1 in naevi and malignant melanoma of the skin and its relation to clinical outcome. Histol Histopathol 2005;20:501-508. (Pubitemid 40468270)
28. Li JQ, Wu F, Masaki T, et al. Correlation of Skp2 with carcinogenesis, invasion, metastasis, and prognosis in colorectal tumors. Int J Oncol 2004;25:87-95.
29. Traub F, Mengel M, Luck HJ, Kreipe HH, von Wasielewski R. Prognostic impact of Skp2 and p27 in human breast cancer. Breast Cancer Res Treat 2006;99:185-191. (Pubitemid 44268266)
30. Zhu CQ, Blackhall FH, Pintilie M, et al. Skp2 gene copy number aberrations are common in non-small cell lung carcinoma, and its overexpression in tumors with ras mutation is a poor prognostic marker. Clin Cancer Res 2004;10:1984-1991. (Pubitemid 38375557)
31. Qi CF, Xiang S, Shin MS, et al. Expression of the cyclin-dependent kinase inhibitor p27 and its deregulation in mouse B cell lymphomas. Leuk Res 2006;30:153-163. (Pubitemid 41773335)
32. Saez A, Sanchez E, Sanchez-Beato M, et al. p27KIP1 is abnormally expressed in diffuse large B-cell lymphomas and is associated with an adverse clinical outcome. Br J Cancer 1999;80:1427-1434. (Pubitemid 29308613)
33. Chiarle R, Budel LM, Skolnik J, et al. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood 2000;95:619-626. (Pubitemid 30041678)
34. Quintanilla-Martinez L, Thieblemont C, Fend F, et al. Mantle cell lymphomas lack expression of p27Kip1, a cyclin-dependent kinase inhibitor. Am J Pathol 1998;153:175-182. (Pubitemid 28317520)
35. Sanchez-Beato M, Saez AI, Martinez-Montero JC, et al. Cyclin-dependent kinase inhibitor p27KIP1 in lymphoid tissue: p27KIP1 expression is inversely proportional to the proliferative index. Am J Pathol 1997;151:151-160.
36. Alkarain A, Slingerland J. Deregulation of p27 by oncogenic signaling and its prognostic significance in breast cancer. Breast Cancer Res 2004;6:13-21. (Pubitemid 38195556)
37. Barnes A, Pinder SE, Bell JA, et al. Expression of p27kip1 in breast cancer and its prognostic significance. J Pathol 2003;201:451-459. (Pubitemid 37408266)
38. Leivonen M, Nordling S, Lundin J, von Boguslawski K, Haglund C. p27 expression correlates with short-term, but not with long-term prognosis in breast cancer. Breast Cancer Res Treat 2001;67:15-22. (Pubitemid 32703384)
39. Nicolaides C, Fountzilas G, Zoumbos N, et al. Diffuse large cell lymphomas: identification of prognostic factors and validation of the international non-Hodgkin's lymphoma prognostic index. A Hellenic Cooperative Oncology Group Study. Oncology 1998;55:405-415. (Pubitemid 28396051)
40. Miller TP, Grogan TM, Dahlberg S, et al. Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial. Blood 1994;83:1460-1466. (Pubitemid 24081556)
41. Sanchez E, Chacon I, Plaza MM, et al. Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins. J Clin Oncol 1998;16:1931-1939. (Pubitemid 28234743)
42. Broyde A, Boycov O, Strenov Y, Okon E, Shpilberg O, Bairey O. Role and prognostic significance of the Ki-67 index in non-Hodgkin's lymphoma. Am J Hematol 2009;84:338-343.
43. Jerkeman M, Anderson H, Dictor M, Kvaloy S, Akerman M, Cavallin-Stahl E. Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma - a Nordic Lymphoma Group study. Ann Hematol 2004;83: 414-419. (Pubitemid 38877961)
44. Hasselblom S, Ridell B, Sigurdardottir M, Hansson U, Nilsson-Ehle H, Andersson PO. Low rather than high Ki-67 protein expression is an adverse prognostic factor in diffuse large B-cell lymphoma. Leuk Lymphoma 2008;49:1501-1509.